About Us

Advamedica Inc. is a deep science MedTech company established in 2015 and is focused on biomaterial based medical devices for pre-hospital, intra-operative and post-operative clinical needs. The company was founded by Leo Mavely – a bioengineer who along with reputed scientists developed novel in biomaterials based medical devices for management of trauma, surgical and chronic-infectious wounds. With decade long expertise in biomaterials, these products are manufactured at their facility at Axio  BioSolutions, India a fully owned subsidiary.

Bleeding Control

Vascular Accesses & Trauma​

Solving age-old problems using novel biomaterials

Headquarters: Cambridge, Massachusetts
Manufacturing Facilities: 18,000 sq.ft Ahmedabad, India, Class 10,000, FDA Registered, GMP, ISO 13485 and ISO 9001 certified
Products Launched Internationally:

  • Axiostat: 2016 – 2021 in USA
  • MaxioCel: 2019 – Expected  2023 in USA

 

Advamedica has developed a “Protonated Bio adhesive Technology” under the name of Axiostat, which is a bioactive hemostatic dressing. It works on a unique charge-based mechanism of mucoadhesion which forms a mechanical barrier on the bleeding site.

Axiostat, based on their Chitosan is considered as one of the most promising biomaterial of 21st century due to its versatile nature, excellent biodegradability, biocompatibility, antimicrobial activity, non-toxicity, and  wide applications.

Axiostat Hemostatic Patch - L88 & V55
Banner image for video scaled - Advamedica
Play Video

Hemostatic patch created by Advamedica’s biomaterial technology for all vascular accesses in interventional radiology, interventional cardiology, and another trauma bleeding. Provides bleeding control

Strong Bioadhesion - Icon

Strong Bioadhesion

Hemostat Patch with Sealant Features

Ease of Removal - Icon

Ease of Removal

*Axiostat uses Protonated Bioadhesive Technology developed by Advamedica and is available in 40+ countries.
For more info, visit axiostatusa.com

Investors


TrueScale Capital is a venture growth specialist firm which partners with tested founders who are demonstrating meaningful revenue and growth in large target markets in a capital-efficient manner.

Omidyar Network invests in entrepreneurs and their visionary ideas to create opportunities for people to improve their own lives, their communities, and the world around them.

UC-RNT Fund an investment fund sponsored by Tata Sons Chairman Emeritus, Ratan Tata (RNT Associates) and University of California.

Accel is a globally reputed venture capital firm that nurtures forward-thinking, category-defining enterprises.

Chiratae Ventures (formerly IDG Ventures India) is a leading India-focused venture capital fund.

Are you willing to improve the bleeding control with the hemostatic patch created with innovative biomaterials technology?
You can partner with us!

Dr S V Mahadevan

Dr. Mahadevan is a Professor of Emergency Medicine at Stanford University where he has been a recipient of numerous teaching awards. He also serves as the Director of Global Affairs and Strategy for Stanford Medicine. He received his medical degree from David Geffen School of Medicine at UCLA.

Dr Shiladitya Sengupta

Dr. Sengupta serves as the Associate Professor of Medicine at HMS and as the Associate Professor of Health Sciences and Technology at MIT. Dr. Sengupta received his PhD from University of Cambridge as a British Chevening and Nehru Scholar, and is a recipient of the TR35 Innovator Award from the MIT Technology Review Magazine and the Era of Hope Scholar Award from the US Department of Defense.

Satish Jajodia

Satish brings a wealth of diverse experiences to his CFO role at Advamedica. In addition to his Fortune 500 roles (FedEx, Citi, AmEx, JPM Chase) in various leadership capacities across multiple countries, he has worked with a number of startups and SMBs as their in-house or consulting CFO. Over the last three years, Satish has helped companies raise over $100 million in venture capital and financing.

Maria Samuel

Quality professional with over 25 years of experience in the medical device, pharmaceutical, and software industries.
Maria is specialized in developing and implementing Quality Management Systems and has deep knowledge and experience in audit preparation, resolution/remediation as per regulatory compliance in ISO 13485, 21 CFR Part 820, EU MDR, MDSAP, and other regional regulations (China, Taiwan, Brazil, Japan, Canada, Australia, Korea, Switzerland, etc.)

Samantha Labanti

Samantha is Director of Clinical Marketing at Advamedica. Previously she was Global Training Manager in Terumo Aortic overseeing all training and clinical skills. Prior to that Samantha was National Sales & Marketing Manager in Bolton Medical, Italy for almost a decade. Samantha has done Executive MBA in Strategic Marketing and has Degree in Professional nursing from the University of Bologna, Italy.

Edward Hallaran

Edward is US – National Sales Director at Advamedica. He comes with many decades of experience selling novel hemostats and woundcare products in over 26 states in the US. He was earlier Regional Sales Director at Z-Medica managing business of their Hemostatic product line for Surgery, Trauma, Cardiology, Burn and Wound Care. He is passionate about creating top performing teams, driven by diversity, inclusion, values and accountability. Edward has a Bachelor of Business Administration from Dowling College.

Oscar Rospigliosi

Oscar Rospigliosi is a Senior MedTech executive with broad experience in medical device sales and marketing. He was the CEO & Director at Scion Biomedical and prior to that, he was a CEO at Bolton Medical Group, guiding the company from $4.5mn in annual revenues to $80mn in the cardio-thoracic market.

Leo Mavely

Leo Mavely is the president of Advamedica Inc. He is passionate about medtech innovations for unmet healthcare needs, and has been featured by Fortune Magazine in 40 under 40 business leaders and by Entrepreneur Magazine in 35 under 35 Game-Changing Entrepreneurs. He holds a Bachelor’s degree in Bioengineering.

YOU ARE LEAVING THE ADVAMEDICA US SITE.

If you continue, you will leave this site and go to a non-US site.

Some of the products on the other site may not be approved in the United States.”

YOU ARE LEAVING THE ADVAMEDICA US SITE.

If you continue, you will leave this site and go to a non-US site.

Some of the products on the other site may not be approved in the United States.”